Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/17/2010EP2162134A1 Carbostyril derivatives including cilostazol for treating fatty liver
03/17/2010EP2162133A1 Methods for reducing allergies caused by environmental allergens
03/17/2010EP2162132A1 Heterocyclic kinase modulators
03/17/2010EP2162130A1 Triazol compounds for treating biofilm formation
03/17/2010EP2162129A1 Use of hdac inhibitors for the treatment of bone destruction
03/17/2010EP2162128A1 Sesquiterpene formulations, kits and methods of use thereof
03/17/2010EP2162126A2 Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
03/17/2010EP2162125A2 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
03/17/2010EP2162124A1 Neramexane for the treatment of nystagmus
03/17/2010EP2162123A1 Honokiol analogs and their use in treating cancers
03/17/2010EP2162122A1 Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
03/17/2010EP2162120A2 Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
03/17/2010EP2162119A2 Stable pharmaceutical formulation for a dpp-iv inhibitor
03/17/2010EP2162117A2 Nucleic acid nanoparticles and uses therefor
03/17/2010EP2161998A1 Novel methods
03/17/2010EP2161997A1 Tricyclic inhibitors of fatty acid amide hydrolase
03/17/2010EP2161996A1 Carboxamide heterocyclic cgrp receptor antagonists
03/17/2010EP2161995A1 A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4, 3-b) indoles, its pharmacological compound and application method
03/17/2010EP2161994A2 Urotensin ii receptor antagonists
03/17/2010EP2089005B1 Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
03/17/2010EP2026769B1 Bilayer tablet for preventing cardiovascular events
03/17/2010EP1981509B1 Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions
03/17/2010EP1966191B1 Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
03/17/2010EP1948666B1 Hiv integrase inhibitors
03/17/2010EP1933945B1 A pharmaceutical composition comprising mahanine useful for the treatment of prostate cancer
03/17/2010EP1924270B1 Iron (iii) complex compounds for orally treating iron deficiency in patients with chronic inflammatory intestinal diseases
03/17/2010EP1896034B1 Micronized tanaproget compositions and methods of preparing the same
03/17/2010EP1846390B1 Novel 6-pyridylphenanthridines
03/17/2010EP1817300B1 Potentiators of glutamate receptors
03/17/2010EP1807068B1 Composition comprising acetaminophen, caffeine and aspirin together with an alkiline agent fr enhanced absorption
03/17/2010EP1786810B1 Ligands for g-protein coupled receptors
03/17/2010EP1783123B1 Synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins
03/17/2010EP1713822B1 Hcv ns-3 serine protease inhibitors
03/17/2010EP1708711B1 Compositions useful especially for treatment or prevention of metabolic syndrome
03/17/2010EP1701960B1 Cysteine protease inhibitors
03/17/2010EP1689795B1 Method of manufacture of polyacrolein
03/17/2010EP1689742B1 Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
03/17/2010EP1654257B1 Aminopyrones and their use as atm inhibitors
03/17/2010EP1651615B1 Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
03/17/2010EP1641423B1 Benzodiazepine cgrp receptor antagonists
03/17/2010EP1620411B1 Inhibitors of akt activity
03/17/2010EP1572214B1 Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
03/17/2010EP1560813B1 Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/17/2010EP1546133B1 N-substituted-2-oxodihydropyridine derivatives as npy antagonists
03/17/2010EP1513814B1 Novel piperidine compound
03/17/2010EP1503729B1 Composition and the use thereof as a pharmaceutical or cosmetic formulation for external use
03/17/2010EP1393518B1 Arylsulfatase-inhibitors in deodorants and antiperspirants
03/17/2010EP1385870B1 Peptides as ns3-serine protease inhibitors of hepatitis c virus
03/17/2010EP1347955B1 New mandelic acid derivatives and their use as throbin inhibitors
03/17/2010EP1335689B1 Loratadine transdermal administration system and use thereof
03/17/2010EP1315502B1 Method for treating erectile dysfunction and increasing libido in men
03/17/2010EP1303536B1 Novel fibroblast growth factor (fgf23) and methods for use
03/17/2010EP1250166B1 Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
03/17/2010EP1091971B1 Polyketide synthesis
03/17/2010EP1031569B1 Salt of a 7-isoindolinequinolonecarboxylic acid derivative, monohydrate thereof and composition containing the same as active ingredient
03/17/2010CN101675066A Method for inhibiting scavenger receptor-a and increasing immune response to antigens
03/17/2010CN101675060A Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
03/17/2010CN101675059A Macrocyclic compound
03/17/2010CN101675058A Process for production of prasugrel hydrochloride having high purity
03/17/2010CN101675056A Heterocyclic compounds and their use as pesticides
03/17/2010CN101675053A Phosphoinositide 3-kinase inhibitor compounds and methods of use
03/17/2010CN101675052A Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h.6h) carbaldehyde derivatives
03/17/2010CN101675051A Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
03/17/2010CN101675050A Purines as cysteine protease inhibitors
03/17/2010CN101675049A Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
03/17/2010CN101675048A 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one derivatives useful as a2b adenosine receptor antagonists
03/17/2010CN101675047A hydrochloride salt of an azabicyclo[3.2.1]octane derivative
03/17/2010CN101675046A therapeutic agents
03/17/2010CN101675045A Hetarylanilines as modulators for amyloid beta
03/17/2010CN101675042A Novel 2-heteroaryl substituted benzothiophenes and benzofuranes 709
03/17/2010CN101675041A Aminopyrimidines useful as kinase inhibitors
03/17/2010CN101675040A Pyridine derivatives
03/17/2010CN101675036A dual-acting benzoimidazole antihypertensive agents
03/17/2010CN101675035A Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
03/17/2010CN101675034A Pyridone derivatives as p38a mapk inhibitors
03/17/2010CN101675033A Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
03/17/2010CN101675032A Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
03/17/2010CN101674843A Composition for transmucosal delivery of polypeptides
03/17/2010CN101674838A Compositions and methods for treating cancer
03/17/2010CN101674837A New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
03/17/2010CN101674836A Novel dosage form
03/17/2010CN101674835A Process for making galantamine
03/17/2010CN101674834A inhibitors of bruton's tyrosine kinase
03/17/2010CN101674833A Raf kinase inhibitors containing a zinc binding moiety
03/17/2010CN101674832A Indenoisoquinolinone analogs and methods of use thereof
03/17/2010CN101674831A Piperidine derivatives and methods of use thereof
03/17/2010CN101674830A Novel therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
03/17/2010CN101674829A Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas
03/17/2010CN101674828A Raf inhibitors for the treatment of thyroid cancer
03/17/2010CN101674827A Benzimidazole derivatives and methods of use thereof
03/17/2010CN101674826A Compounds, screens, and methods of treatment
03/17/2010CN101674825A Use of hdac inhibitors for the treatment of gastrointestinal cancers
03/17/2010CN101674824A Treatment of age-related macular degeneration using inhibitors of complement factor d
03/17/2010CN101674823A Method for the treatment of conditions associated with increased 5-lipoxygenase and/or leukotriene activity
03/17/2010CN101674822A compositions and methods for inhibiting cytochrome p450
03/17/2010CN101674821A Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid
03/17/2010CN101674820A Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
03/17/2010CN101674819A Use of s1p receptor modulator
03/17/2010CN101674818A Dermatological and cosmetic depigmenting compositions, methods for the preparation thereof and uses thereof
03/17/2010CN101674817A Novel use of hydroxytyrosol
1 ... 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 ... 7860